Effects of Olanzapine–Fluoxetine Combination Treatment of Major Depressive Disorders on the Quality of Life During Acute Treatment Period

2014 ◽  
Vol 70 (3) ◽  
pp. 1799-1802
Author(s):  
Wei Qu ◽  
Shanshan Gu ◽  
Han Luo ◽  
Qianying Tang ◽  
Junwei Guo
Keyword(s):  
Quality Of Life ◽  
Treatment Period ◽  
Combination Treatment ◽  
Acute Treatment ◽  
Depressive Disorders ◽  
Major Depressive ◽  
Major Depressive Disorders

The quality of life in dysthymic and major depressive disorders

1997 ◽  
Vol 42 (1) ◽  
pp. 256S
Author(s):  
F. Cavaglia ◽  
A. Matos-Pires ◽  
M. Botelho ◽  
M. Oliveira ◽  
F. Arriaga
Keyword(s):  
Quality Of Life ◽  
Depressive Disorders ◽  
Major Depressive ◽  
Major Depressive Disorders

The Use of Art Therapy in Complex Treatment on the Quality of Remission in Patients with Melancholy in Major Depressive Disorder

2017 ◽  
Vol 41 (S1) ◽  
pp. s777-s777 ◽  
Author(s):  
H. Kozhyna ◽  
V. Korostiy ◽  
S. Hmain ◽  
V. Mykhaylov
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Art Therapy ◽  
Depressive Disorders ◽  
Combined Treatment ◽  
Control Group ◽  
Complex Treatment ◽  
Major Depressive

IntroductionAccording to studies done in recent years regarding the treatment of patients with melancholy in major depressive disorder, a shift of interest from studies evaluating the effectiveness of therapy to the study of remission is seen. Despite significant progress in the development of pharmacotherapy of depressive disorders, difficulty in achieving rapid reduction in depressive symptoms and stable remission in patients with melancholic depression necessitated the search for new approaches to the treatment of this pathology.AimsEvaluating the effectiveness of art therapy in treatment in patients with melancholy in major depressive disorder on the quality of remission.MethodsThe study involved 135 patients – 60 male and 75 female patients aged from 18 to 30 years old. The main group of patients apart the combined treatment also participated in group art therapy with the use of drawing techniques, while the control group – statutory standard therapy.ResultsThe results of the use of art therapy in complex treatment in patients with major depressive disorder is detected primarily in reducing of the level of anxiety at the early stages of treatment (60% of patients have noticed decreasing of melancholic state), as well as improving the quality of life in remission period.ConclusionThese results support the use of art therapy in treatment in patients with melancholy in major depressive disorder during period of active treatment, and after achieving clinical remission contributes to achieving and maintaining high-quality and stable remission with full restoration of quality of life and social functioning.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Takotsubo Syndrome is Associated with Mood Disorders and Antidepressants Use, not with Anxiety and Impairment of Quality of Life Due to the Psychiatric Disorder

2018 ◽  
Vol 14 (1) ◽  
pp. 26-32 ◽  
Author(s):  
F. Sancassiani ◽  
Mauro G. Carta ◽  
Roberta Montisci ◽  
Antonio Preti ◽  
Sergio Machado ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Psychiatric Disorder ◽  
Mood Disorder ◽  
Mood Disorders ◽  
Depressive Disorders ◽  
Statistical Significance ◽  
Structured Interview ◽  
Icd 10 ◽  
Major Depressive Disorders

Background: The aim was to study the association between mood and anxiety disorders and the Tako-Tsubo Syndrome (TTS) and to determine the role of antidepressants and the impairment of quality of life due the comorbid psychiatric disorder. Methods: Case-control study: 19 consecutive patients (17 female) with TTS compared to 76 controls without TTS, were randomly selected from the database of a nationwide epidemiological study after matching (gender, age and residence) by controls. Psychiatric diagnoses were carried out according to the ICD-10 using semi-structured interview tools (ANTAS-SCID) administered by clinical staff. Quality of Life (Qol) was assessed by means of SF-12. Results: Only Major Depressive Disorders (MDD) showed higher frequencies in cases with statistical significance difference (p=0.014) as well as at least one Mood Disorder Diagnosis [MDD or BD] (p=0.002). The lifetime prevalence of at least one anxiety disorder with no comorbid mood disorder did not show a higher frequency in cases (p=0.57). The score at SF-12 in the TTS group was similar to those of controls (p=0.71)In the TTS group, the score at SF-12 in people with one mood or anxiety diagnosis (N=7) was similar to those without mood or anxiety diagnosis (p=0.75). The use of antidepressants was higher in TTS group (15.79% vs 1.31%; p=0.030). Conclusion: The study shows an association between TTS with depressive disorders and antidepressants use and does not confirm the association with anxiety syndromes. The study suggests the need to investigate the possible interactions between antidepressants use and mood disorders in studies with appropriate design and sample size.

scholarly journals Use of Mental Health Services for Patients Diagnosed with Major Depressive Disorders in Primary Care

2021 ◽  
Vol 18 (3) ◽  
pp. 885
Author(s):  
Laura González-Suñer ◽  
Cristina Carbonell-Duacastella ◽  
Ignacio Aznar-Lou ◽  
Maria Rubio-Valera ◽  
Maria Iglesias-González ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Mental Health ◽  
Primary Care ◽  
Mental Health Services ◽  
Health Services ◽  
Depressive Disorders ◽  
Mental Healthcare ◽  
Major Depressive ◽  
Use Of Services

Major depressive disorder (MDD) is one of the most disabling diseases worldwide, generating high use of health services. Previous studies have shown that Mental Health Services (MHS) use is associated with patient and Family Physician (FP) factors. The aim of this study was to investigate MHS use in a naturalistic sample of MDD outpatients and the factors influencing use of services in specialized psychiatric care, to know the natural mental healthcare pathway. Non-randomized clinical trial including newly depressed Primary Care (PC) patients (n = 263) with a 12-month follow-up (from 2013 to 2015). Patient sociodemographic variables were assessed along with clinical variables (mental disorder diagnosis, severity of depression or anxiety, quality of life, disability, beliefs about illness and medication). FP (n = 53) variables were also evaluated. A multilevel logistic regression analysis was performed to assess factors associated with public or private MHS use. Subjects were clustered by FP. Having previously used MHS was associated with the use of MHS. The use of public MHS was associated with worse perception of quality of life. No other sociodemographic, clinical, nor FP variables were associated with the use of MHS. Patient self-perception is a factor that influences the use of services, in addition to having used them before. This is in line with Value-Based Healthcare, which propose to put the focus on the patient, who is the one who must define which health outcomes are relevant to him.

Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study

2014 ◽  
Vol 45 (8) ◽  
pp. 1641-1652 ◽  
Author(s):  
J.-M. Kim ◽  
R. Stewart ◽  
K.-Y. Bae ◽  
H.-J. Kang ◽  
S.-W. Kim ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Acute Coronary Syndrome ◽  
Treatment Period ◽  
Depressive Disorders ◽  
World Health ◽  
Depression Treatment ◽  
World Health Organization Quality ◽  
Coronary Syndrome ◽  
Co Morbidity

BackgroundDepression is common after acute coronary syndrome (ACS) with adverse effects on prognosis. There is little evidence on whether depression treatment improves quality of life (QoL) in ACS patients. The aim of this study was to investigate the effects of co-morbid depression and its treatment on QoL in ACS.MethodIn total, 1152 patients were recruited at baseline, 2–14 weeks after a confirmed ACS episode, and 828 were followed 1 year thereafter. Of 446 baseline participants with co-morbid depressive disorders, 300 were randomized to a 24-week double blind trial of escitalopram or placebo, while the remaining 146 received medical treatment only (MTO). QoL was measured by the World Health Organization Quality of Life –Abbreviated form (WHOQOL-BREF).ResultsAt baseline, QoL was significantly lower in patients with co-morbid depressive disorder than those without. QoL improvement was significantly greater in those receiving escitalopram than those receiving placebo over the 24-week treatment period. In the 1-year follow-up, the better outcomes associated with escitalopram remained evident against both placebo and MTO.ConclusionsDepression was significantly associated with worse QoL even in patients with recently developed ACS. Depression treatment was associated with QoL improvement in ACS patients in the 24-week treatment period, the effects of which extended to 1 year.

Depression in Amputation Patients

2021 ◽  
Vol 1 (4) ◽  
pp. 67-70
Author(s):  
Arazy Gifta Prima
Keyword(s):  
Depressive Disorders ◽  
Lower Limbs ◽  
Phantom Limb ◽  
Limb Amputation ◽  
Major Depressive ◽  
Number Of Patients ◽  
Major Depressive Disorders ◽  
The Common ◽  
General Mobility

Amputation alters the quality of life with an undeniable negative somatic and functional impact. The patient’s general mobility is impaired and there is an increase in metabolic needs as well as pain and discomfort. Etiologies are quite diverse: essentially vascular pathologies (74%) for the lower limbs and trauma related (61%) for the upper limbs. Thus, an important number of patients have to face amputation-related consequences. Pain (stump, phantom limb, back pain) is frequently described in 65 to 75% of patients after an amputation as well as the common onset of major depressive disorders for 35% of them. With the incidence of depression after limb amputation increasing in the patients, we sought to summarize the management of depression in amputation patients.

Psychological Interventions for Cognitive Dysfunction in Major Depressive Disorder

2019 ◽  
pp. 241-256
Author(s):  
Claudia Woolf ◽  
Loren Mowszowski ◽  
Sharon Naismith
Keyword(s):  
Depressive Disorders ◽  
Evidence Base ◽  
Neuropsychological Impairment ◽  
Major Depressive ◽  
Neuropsychological Dysfunction ◽  
Symptoms Of Depression ◽  
Full Remission ◽  
Affective Symptoms ◽  
Major Depressive Disorders

Major depressive disorders (MDD) are common and disabling, and are linked to functional impairment and increased mortality. While current treatments for MDD are moderately effective, ultimately up to one-third of patients do not achieve full remission. Interestingly, while affective symptoms of depression resolve with the resolution of a depressive episode, cognitive or neuropsychological impairment persists, and has been identified as one of the most prominent predictors of ongoing disability, reduced quality of life, and illness recurrence. Yet available treatments in MDD do not typically address neuropsychological dysfunction. Cognitive training, however, despite a small and heterogeneous evidence base, represents a promising and novel therapeutic intervention for neuropsychological impairment in MDD, which may yield neuropsychological, affective, and functional benefits.

scholarly journals Quality of life and subjective sleep-related measures in bipolar disorder and major depressive disorder

2021 ◽  
Author(s):  
Françoise Jermann ◽  
Nader Perroud ◽  
Sophie Favre ◽  
Jean-Michel Aubry ◽  
Hélène Richard-Lepouriel
Keyword(s):  
Quality Of Life ◽  
Bipolar Disorder ◽  
Mood Disorders ◽  
Sleep Disturbances ◽  
Depressive Disorders ◽  
Depressive Symptomatology ◽  
Major Depressive ◽  
Obstructive Sleep ◽  
Insomnia Complaints

Abstract Purpose Diminished quality of life (QoL) has been reported in patients with mood disorders. QoL has also been shown to be decreased by sleep disturbances. Since sleep disorders are common in mood disorders, the aim of this study was to determine whether sleep characteristics are associated to QoL among patients with Bipolar Disorder (BD) and unipolar Major Depressive Disorders (MDD). Methods QoL was assessed in 170 patients with mood disorders (61 BD and 109 MDD), who also completed questionnaires measuring the severity of insomnia, sleepiness, chronotype preference and obstructive sleep apnea (OSA) probability index. Results Analyses showed that BD and MDD groups had similar QoL and sleep measures but the MDD group had higher OSA scores. In BD, correlations indicated a relationship between QoL and insomnia complaints and sleepiness, whereas in MDD, correlations indicated an association between QoL and insomnia complaints and OSA score. In both groups, QoL was related to depressive symptomatology. Linear regressions showed that, in BD, QoL was related to insomnia complaints and sleepiness even in the euthymic state, whereas in MDD, QoL was related to insomnia complaints but not in euthymic patients. Conclusion QoL is related to sleep differently in BD and MDD. The results suggest that insomnia and sleepiness are particularly high in BD even when patients are euthymic. These findings suggest that focusing on insomnia and sleepiness during different mood states of BD could increase QoL.

Sign in / Sign up

Export Citation Format

Share Document